首页> 外国专利> SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS

SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS

机译:单结构域抗体及其特异性结合SARS-COV-2病毒的RBD蛋白的修饰,以及用于治疗和应急预防SARS-COV-2病毒引起的疾病的方法

摘要

FIELD: biotechnology; immunology; virology.;SUBSTANCE: described is a single-domain antibody that specifically binds to RBDS of the SARS-CoV-2 virus protein, has a virus neutralizing activity and has the amino acid sequence SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3. Also proposed is an oligomerized single-domain antibody that specifically binds to the RBDS protein of the SARS-CoV-2 virus, having a virus neutralizing activity, containing any variant of the created single-domain antibody as a monomeric block. In addition, an antibody has been created, which is a single-domain antibody fused to the Fc fragment of human immunoglobulin G1, which specifically binds to RBDS of the SARS-CoV-2 virus protein and has a virus neutralizing activity having the final amino acid sequence of SEQ ID NO:7, or SEQ ID NO:8, or SEQ ID NO:9. An oligomerized antibody has also been created, which is an oligomerized single-domain antibody fused to the Fc fragment of human immunoglobulin G1, which specifically binds to RBDS of the SARS-CoV-2 virus protein and has a virus neutralizing activity. A method for therapy or emergency prevention of diseases caused by the SARS-CoV-2 virus has been developed, which consists in introducing into the mammalian body in an effective amount of any created antibody.;EFFECT: arsenal of means for therapy and emergency prevention of diseases caused by the SARS-CoV-2 virus is expanded.;5 cl, 8 dwg, 5 tbl, 15 ex
机译:领域:生物技术;免疫学;病毒学。;物质:描述的是一种单结构域抗体,其特异性结合SARS-COV-2病毒蛋白的RBD,具有病毒中和活​​性,并且具有氨基酸序列SEQ ID NO:1,或SEQ ID NO:2 ,或SEQ ID NO:3。还提出的是寡聚化单结构域抗体,其特异性结合SAR-COV-2病毒的RBDS蛋白,其具有病毒中和活​​性,含有所产生的单结构域抗体的任何变体作为单体嵌段。此外,已经产生抗体,其是与人免疫球蛋白G1的Fc片段融合的单结构域抗体,其特异性结合SARS-COV-2病毒蛋白的RBD,并且具有最终氨基的病毒中和活​​性SEQ ID NO:7,或SEQ ID NO:8或SEQ ID NO:9的酸序列。还产生了寡聚化抗体,其是与人免疫球蛋白G1的Fc片段融合的低聚单结构域抗体,其特异性结合SARS-COV-2病毒蛋白的RBD并具有病毒中和活​​性。已经开发出一种用于治疗或紧急预防由SARS-COV-2病毒引起的疾病的方法,其包括以有效量的任何产生的抗体引入哺乳动物体。;效果:治疗方法的效果和应急预防由SARS-COV-2病毒引起的疾病扩大。; 5 CL,8 DWG,5 TBL,15 ex

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号